New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
13:25 EDTILMN, ILMN, ILMN, LMNX, LMNX, LMNX, CPHD, CPHD, CPHD, GNMK, GNMK, GNMK, NSTG, NSTG, NSTG, MYGN, MYGN, MYGN, FLDM, FLDM, FLDM, PACB, PACB, PACB, TMO, TMO, TMO, QGEN, QGEN, QGENLeerink's life science tools analyst holds an analyst/industry conference call
Life Science Tools Analyst Leonard discusses the use of nextgen sequencing in a clinical context, early applications and uptake, the merits, demerits of various nextgen sequencing instruments and where new offerings fit on an Analyst/Industry conference call. Relevant companies ILMN, TMO, PACB, FLDM, MYGN, NSTG, GNMK, CPHD, LMNX and QGEN may be discussed on the Analyst/Industry conference call to be held on April 3 at 2 pm.
News For ILMN;TMO;PACB;FLDM;MYGN;NSTG;GNMK;CPHD;LMNX;QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
10:01 EDTPACBOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: EVERTEC (EVTC) initiated with a Buy at Topeka... Express (EXPR) initiated with a Buy at Brean Capital... Flexion (FLXN) initiated with a Buy at MLV & Co.... HomeAway (AWAY) initiated with a Long-Term Buy at Hilliard Lyons... IAC (IACI) initiated with an Outperform at JMP Securities... INC Research (INCR) initiated with an Outperform at Raymond James... L Brands (LB) initiated with a Hold at Brean Capital... Masonite (DOOR) initiated with an Equal Weight at Stephens... MaxPoint Interactive (MXPT) initiated with a Buy at Deutsche Bank... NGL Energy Partners (NGL) initiated with an Equal Weight at Barclays... Neovasc (NVCN) initiated with an Outperform at Northland... New York & Co. (NWY) initiated with a Buy at Brean Capital... Pacific Biosciences (PACB) initiated with an Equal Weight at Stephens... Rice Midstream (RMP) initiated with an Outperform at Wells Fargo... Sensient (SXT) initiated with a Buy at BB&T... Skullcandy (SKUL) initiated with a Buy at Wunderlich... Ultragenyx (RARE) initiated with a Buy at MLV & Co.... Virgin America (VA) initiated with a Hold at Stifel... ZAGG (ZAGG) initiated with a Buy at Wunderlich.
09:23 EDTILMNNextSeq CN500 receives premarket clearance from Chinese FDA
Subscribe for More Information
08:05 EDTPACBPacific Biosciences initiated with an Equal Weight at Stephens
Target $6.50.
March 30, 2015
16:06 EDTLMNXLuminex begins clinical trials for ARIES System, HSV 1&2 assay
Subscribe for More Information
10:52 EDTMYGNLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
March 26, 2015
10:04 EDTMYGNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:07 EDTMYGNMyriad Genetics downgraded to Sell from Neutral at Goldman
Subscribe for More Information
March 24, 2015
16:09 EDTCPHDCepheid receives FDA emergency use authorization for Xpert Ebola diagnostic test
Cepheid announced it has received Emergency Use Authorization from the FDA for Xpert Ebola, a molecular diagnostic test for Ebola Zaire Virus that delivers results in less than two hours. The test runs on the Cepheid GeneXpert Systems. Xpert Ebola has been authorized by FDA under an Emergency Use Authorization for use by CLIA moderate and high complexity laboratories or similarly qualified non-U.S. laboratories. The test will begin shipping in April. Cepheid's Xpert Ebola has not been FDA cleared or approved, but will remain available in the U.S. as an EUA product as long as the declared emergency remains in effect or it ceases to be authorized by FDA.
March 20, 2015
07:41 EDTMYGNAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
05:17 EDTMYGNMyriad EMPATHY-P clinical study results to be highlighted at annual congress
Myriad Genetics announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. The EMPATHY-P study evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in these newly diagnosed patients from five European countries including: Italy, Germany, Spain, Switzerland and the UK. The patients' biopsy samples also were evaluated using standard clinical pathology methods, which were then compared to the Prolaris test results. The EMPATHY-P data showed, overall, that the Prolaris test found 42% of the European men evaluated had a risk profile that was either lower or higher than would be expected using clinical pathology. Interestingly, this finding is consistent with the previously published U.S. Prostate Biopsy Research study, which found 51% of U.S. patients had a risk profile that differed from clinical pathology.
March 19, 2015
08:57 EDTCPHDCepheid has a conference call hosted by JPMorgan
Subscribe for More Information
March 18, 2015
08:33 EDTILMNTrovagene appoints Matthew Posard as Chief Commercial Officer
Subscribe for More Information
05:33 EDTNSTGNanoString Prosigna Assay included in German breast cancer treatment guidelines
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use